Compare RES & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RES | OGN |
|---|---|---|
| Founded | 1984 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 1995 | 2020 |
| Metric | RES | OGN |
|---|---|---|
| Price | $6.60 | $13.38 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 5 |
| Target Price | $5.64 | ★ $11.40 |
| AVG Volume (30 Days) | 1.6M | ★ 5.0M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.02% | 0.60% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.55 |
| Revenue | ★ $41,919,000,000.00 | $6,216,000,000.00 |
| Revenue This Year | $3.29 | $0.45 |
| Revenue Next Year | $4.05 | $1.67 |
| P/E Ratio | $45.40 | ★ $24.28 |
| Revenue Growth | ★ 2216.21 | N/A |
| 52 Week Low | $4.18 | $5.69 |
| 52 Week High | $8.16 | $13.48 |
| Indicator | RES | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 38.79 | 74.68 |
| Support Level | $6.42 | $10.05 |
| Resistance Level | $6.85 | $13.46 |
| Average True Range (ATR) | 0.25 | 0.05 |
| MACD | -0.07 | -0.22 |
| Stochastic Oscillator | 7.05 | 47.50 |
RPC Inc is an oilfield services company. It provides specialized oilfield services and equipment to independent and oil and gas companies engaged in the exploration, production, and development of oil and gas properties throughout the United States. Its operating segment includes Technical Services and Support Services. The Technical Services segment, which generates maximum revenue, comprises service lines that generate revenue based on equipment, personnel, or materials at the well site and are closely aligned with completion and production activities of the customers. The Support Services segment comprises service lines that generate revenue from services and equipment offered off the well site and are closely aligned with the customers' drilling activities.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.